阿尔茨海默病和ABCA7多态的影响:一篇综述
Vaia Gialama1, Vasileios Siokas1, Ioannis Liampas1
1Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.
Journal of integrative neuroscience
|September 30, 2024
概括
在ATP结合卡塞特A子家族7 (ABCA7) 的遗传变异影响阿尔茨海默病 (AD) 的风险. 非洲裔美国人和亚洲人群表现出更高的易感性,突出了AD发展的种族差异.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 痴呆症研究 痴呆症研究
背景情况:
- 阿尔茨海默氏症 (AD) 是导致痴呆的主要原因,其病因复杂且不完全理解.
- 遗传和环境因素有助于AD易感性.
- 结合ATP的卡塞特A亚家族7 (ABCA7) 是一种新兴的基因,对阿尔茨海默病的发病有兴趣.
研究的目的:
- 审查和评估ABCA7遗传多态性在不同人群中阿尔茨海默病发展中的作用.
- 在不同族群中确定与AD风险相关的特定ABCA7变异.
主要方法:
- 在PubMed,谷歌学者和Scopus数据库上进行了系统的文献搜索.
- 根据预先定义的标准,纳入到2023年2月8日发表的研究,检查了AD中的ABCA7变体.
- 这一综合性审查中包括了17项相关研究.
主要成果:
- 在ABCA7变种中,AD风险与AD风险的关联不同,取决于人口的祖先.
- 非洲裔美国人群体表现出更高的风险,与新型变种rs115550680,rs142076058,rs10405305,rs3764647和rs567222111.11相关.
- 亚洲人群也表现出与特定的ABCA7变异相关的AD风险增加,这表明存在显著的种族差异.
结论:
- ABCA7遗传变异性是导致阿尔茨海默氏症发展的一个因素.
- 存在显著的种族差异,非洲裔美国人和亚洲人群似乎有更大的风险.
- 了解ABCA7的作用及其变体可能有助于早期的AD诊断,并确定潜在的治疗点.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.8K
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.7K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
